Status:
COMPLETED
Albuterol Integrated Adherence Monitoring in Children With Asthma
Lead Sponsor:
Children's Hospital Los Angeles
Collaborating Sponsors:
Teva Pharmaceuticals USA
Conditions:
Asthma in Children
Eligibility:
All Genders
8-18 years
Phase:
NA
Brief Summary
The investigators propose to evaluate whether an integrated electronic adherence monitoring albuterol rescue inhaler can improve proper use in a mostly minority and inner-city population of children t...
Detailed Description
This study is designed to (1) determine whether an integrated EAM albuterol rescue inhaler can increase proper use (2) determine if the monitoring capabilities of the device (flow rate, warnings) and/...
Eligibility Criteria
Inclusion
- Patients 8 to \<19 years of age with a diagnosis of asthma as ICD-9 code 493 or ICD-10 code J45 seen in the allergy clinic at CHLA who have an albuterol rescue inhaler already prescribed and access to a personal smartphone will be eligible for recruitment.
Exclusion
- Patients unable to use device, unable to use albuterol (i.e. must use levalbuterol) or Age \< 4 (ProAir® Digihaler only approved for Subjects 4 years and older). Patients with other chronic lung disease besides asthma or other significant comorbidities that could affect lung function/asthma (e.g. significant heart defects, immunodeficiency, cystic fibrosis, etc).
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 22 2022
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT04896645
Start Date
June 1 2021
End Date
June 22 2022
Last Update
November 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027